IL1A and COVID-19: Not surprisingly, interventions based on non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, intravenous immune globulins, immunosuppressants, chloroquine/hydroxychloroquine, IL-1 antagonists, IL-6R monoclonal antibodies, TNF inhibitors, and Janus kinase (JAK) inhibitors have been capable of relieving severe disease conditions in COVID-19 patients [9,10,11].